The primary outcome of this study is to determine whether or not the B cell targeting with
Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission
of proteinuria.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Applied Health Research Centre Case Western Reserve University CHU de Quebec-Universite Laval Columbia University Florida International University Fulk Family Foundation Medical College of Wisconsin NYU Langone Health Ohio State University Stanford University Sunnybrook Health Sciences Centre The Cleveland Clinic University Health Network, Toronto University of Alabama at Birmingham University of Arizona University of British Columbia University of Kansas Medical Center University of Manchester University of Michigan University of Mississippi Medical Center University of Toronto University of Washington Washington University School of Medicine